Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Systemic lupus erythematosus (SLE)
- Topics
- Who is the patient?
- Will I survive?
- Commonest features
- Severe manifestations
- Renal disease
- Blood disorders
- CNS lupus
- CVD (Coronary Vascular Disease) in SLE
- Summary: what can the patient expect?
- Therapy 1 : Don’t forget the simple things
- Therapy 2 : Antimalarials
- Severe disease
- Current treatment of severe SLE
- We need new therapies
- Rationale for biologics in SLE
- Which biologics?
- How to assess trials in lupus?
- Rituximab: B cell depletion
- Rituximab trials
- Is that the end for rituximab?
- Rituxilup protocol
- Treating lupus nephritis (LN) without steroids
- What’s next?
- Epratuzumab
- Main points of epratuzumab trial
- Phase III trial results
- Belimumab
- BLISS studies
- Difference between belimumab and atacicept
- Atacicept trial
- Atacicept trial results
- What can we conclude?
- Anti-TNF in SLE
- Aringer study
- Interferon-alpha
- Anti-interferon monoclonal antibodies
- Anifrolumab
- Summary of SLE
Topics Covered
- Clinical features
- Current therapy
- Pathogenesis and new therapies
Talk Citation
Rahman, A. (2017, October 3). The management of systemic lupus erythematosus [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/DPFJ3562.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Anisur Rahman has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:00
My name is Anisur Rahman,
and I'm a Professor of Rheumatology at University College London.
I'm going to be talking about systemic lupus erythematosus,
an autoimmune disease which I study and treat in my clinic.
I have no financial disclosures.
0:17
So what is SLE?
It's an autoimmune rheumatic disease and it's a very rare disease.
The recent data shows that it's prevalence in the United Kingdom is about 1 in 1,000.
It's far common in women than it is in men,
with the sex ratio being about nine to one,
and it's more common in some ethnic groups,
particularly African and Caribbean people.
SLE is truly systemic.
It can affect any organ or system in the body.
But, the most common effects are on the skin,
the joints, and the hair,
whereas the most severe effects are on the kidney,
the central nervous system, and the blood.
0:51
During this talk, I'm going to cover the following topics:
let's see the clinical features of the disease, the current therapy,
the way we manage lupus now,
and new therapies which have arisen over
the last 10 years as a result of better understanding of the pathogenesis of lupus.
1:09
In terms of clinical features,
the best way to think about this is to imagine you are a patient with lupus,
and you're thinking about what it's going to do to affect your future.
So, what sort of person are you going to be?
You're probably a woman,
as I say the ratio is nine to one,
and you're probably young.
Most people with lupus are in the childbearing years,
between 20 and 40.
So, you're a young woman,
you've never really been ill before,
and suddenly, you have this disease.
You may well be African,
Caribbean or Asian, and you may never have heard of this disease, it's very rare.
If you are diagnosed with diabetes,
you'd probably know somebody who had diabetes,
somebody in your family, maybe.
But if you're diagnosed with lupus,
you've probably never met anybody and maybe never even heard of it,
except on House, a program which was
notorious for the fact that they never diagnosed lupus.